PMID: 7013461May 1, 1981Paper

Platelet function studies in coronary artery disease. X. Effect of dipyridamole

The American Journal of Cardiology
J MehtaC R Conti

Abstract

To evaluate the effects of dipyridamole on blood platelet function in patients with coronary artery disease, platelet counts and aggregation were examined in aortic and coronary venous blood. Before administration of dipyridamole, platelet counts and aggregation in response to adenosine diphosphate were less (p less than 0.02) in coronary venous than in aortic blood. Dipyridamole administration (100 mg) resulted in an increase in platelet counts and platelet aggregation in coronary venous blood so that the differences in aortic and coronary venous blood values were eliminated. These phenomena were probably related to inhibitory actions of dipyridamole on platelet adhesion to atherosclerotic vessels. To further study the mechanism of action, the direct effects of dipyridamole on in vitro platelet aggregation were evaluated. Although dipyridamole, in the concentrations used, had no effect on in vitro platelet aggregation, it greatly potentiated the aggregation inhibitory actions of exogenous prostacyclin. In vivo potentiation of endogenous prostacyclin and inhibitory actions on platelet adhesion are the most likely mechanisms of the potentially beneficial actions of dipyridamole.

References

Mar 1, 1977·Circulation Research·W I Rosenblum, F El-Sabban
Jan 1, 1979·Thrombosis Research·L C BestR G Russell
Jul 1, 1979·Progress in Cardiovascular Diseases·A I Schafer, R I Handin
Jan 1, 1976·Drugs·A S Gallus, J Hirsh
Apr 1, 1977·British Journal of Clinical Pharmacology·S M RajahD A Watson
Oct 1, 1973·The American Journal of Cardiology·N Salky, M Dugdale
Mar 7, 1974·The New England Journal of Medicine·H S WeilyE Genton
Jun 24, 1971·The New England Journal of Medicine·J M SullivanR Gorlin
Dec 10, 1970·The New England Journal of Medicine·L A Harker, S J Slichter

❮ Previous
Next ❯

Citations

Jan 1, 1985·European Journal of Clinical Pharmacology·I MelamedZ Spirer
Oct 1, 1987·British Journal of Clinical Pharmacology·D GregovJ Lloyd
Oct 3, 2002·Current Opinion in Cardiology·Paulette Mehta
Jan 1, 1981·Acta Medica Scandinavica. Supplementum·J Mehta, P Mehta
Nov 1, 1984·Drug Intelligence & Clinical Pharmacy·M P RiveyJ W Taylor
Feb 1, 1986·Current Problems in Cardiology·W H Frishman, K P Miller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.